Brazilian regulator says Covaxin manufacturing facility fails to meet CGMP standards
The Hindu
Bharat Biotech said it is working towards resolving the issues cited during the inspection and the order of 20 million doses from the Brazilian government is still active
The Brazilian health regulator Anvisa has denied permission to import Bharat Biotech's COVID-19 vaccine Covaxin into the country after its authorities found that the plant in which the vaccine is being made did not meet the Current Good Manufacturing Practice (CGMP) requirements. Reacting to it, the city-based vaccine maker said it is working towards resolving the issues cited during the inspection and the order of 20 million doses from the Brazilian government is still active. National Health Surveillance Agency Anvisa in its website said it received a request from the Brazilian Health Ministry to import 20 million doses of Covaxin.More Related News